CO6351781A2 - Derivados de isoquinolinona como antagonistas de nk3 - Google Patents
Derivados de isoquinolinona como antagonistas de nk3Info
- Publication number
- CO6351781A2 CO6351781A2 CO11026657A CO11026657A CO6351781A2 CO 6351781 A2 CO6351781 A2 CO 6351781A2 CO 11026657 A CO11026657 A CO 11026657A CO 11026657 A CO11026657 A CO 11026657A CO 6351781 A2 CO6351781 A2 CO 6351781A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- alkynyl
- alkenyl
- ring
- atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de acuerdo con la fórmula Ien donde A representa N, CH o CR1; cada R1 representa independientemente hidrógeno, alquiloC1-6, alqueniloC2-6, alquiniloC2-6, -C(O)-alquiloC1-6, -C(O)-alqueniloC2-6, -C(O)- alquiniloC2-6, -C(O)-O-alquiloC1-6, -C(O)-O-alqueniloC2-6, -C(O)-O-alquiniloC2-6 o fenilo, en donde dicho fenilo, alquiloC1-6, alqueniloC2-6 o alquiniloC2-6 está opcionalmente sustituido con uno o más sustituyentes seleccionados de halógeno, hidroxilo, haloalquiloC1-6, nitro, alcoxiC1-6 y NR2R3; X representa hidrógeno, alquiloC1-6 opcionalmente sustituido con F, o - CRaRb-X', en donde X' representa un grupo funcional monocíclico saturado que tiene 5-6 átomos en el anillo, uno de los cuales es N, y en donde uno o dos átomos en el anillo adicionales pueden ser un heteroátomo seleccionado de N, O y S, donde el anillo monocíclico puede estar sustituido con uno o más sustituyentes W, en donde W se selecciona de alquiloC1-6, alqueniloC2-6, alquiniloC2-6, haloalquiloC1-6 o (=O); Ra y Rb, cada uno individualmente, representa hidrógeno, -CH3 o halógeno; Q representa un enlace, -CH2-, -NH- o -O-; Y representa alquiloC1-6, aIqueniloC2-6 o alquiniloC2-6, en donde dicho alquilo, alquenilo o alquinilo puede estar sustituido con uno o más sustituyentes P, en donde P se selecciona de halógeno, hidroxi, alcoxiC1-6, ciano, -S-alquiloC1-6 y un grupo funcional monocíclico saturado que tiene 5-6 átomos en el anillo, en donde uno de los átomos en el anillo puede ser N y el resto es C; o Y puede representar un grupo funcional monocíclico saturado que tiene 4-6 átomos en el anillo, en donde uno de dichos átomos en el anillo se puede seleccionar de N y O, siendo el resto C, y donde dicho grupo funcional monocíclico saturado puede estar sustituido con uno o más sustituyentes Z, en donde Z se selecciona de alquiloC1-6, alqueniIoC2-6, alquiniloC2-6, (=O), C(O)H, -C(O)-alquiloC1-6, halógeno, alcoxiC1-6,<hidroxialquiloC1-6 e hidroxi; en donde cada uno de R2 y R3 representa independientemente hidr¢geno, alquiloC1-6, alqueniloC2-6, alquiniloC2-6, hidroxialquiloC1-6 o haloalquiloC1-6; cada uno de R4-R8 y R9-R12 representa independientemente hidr¢geno, alquiloC1-6, alqueniloC2-6, alquiniloC2-6, hal¢geno, NR2R3, hidroxi, ciano, nitro, alcoxiC1-6, haloalquiloC1-6 o hidroxialquiloC1-6; siempre y cuando dicho compuesto sea diferente de (1-fenil-etil)-amida de cido 2-metil-1-oxo-1,2-dihidro-isoquinolin-4-carbox¡lico; y sales farmacéuticamente aceptables de dichos compuestos. Este compuesto es usado en terapia, en particular en el tratamiento de la psicosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801290 | 2008-09-15 | ||
| DKPA200900010 | 2009-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6351781A2 true CO6351781A2 (es) | 2011-12-20 |
Family
ID=41227186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11026657A CO6351781A2 (es) | 2008-09-15 | 2011-03-04 | Derivados de isoquinolinona como antagonistas de nk3 |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP2342182B1 (es) |
| JP (1) | JP5536776B2 (es) |
| KR (1) | KR101638641B1 (es) |
| CN (1) | CN102149685B (es) |
| AR (1) | AR073511A1 (es) |
| AU (1) | AU2009291309B2 (es) |
| BR (1) | BRPI0917245B8 (es) |
| CA (1) | CA2732612C (es) |
| CL (1) | CL2011000533A1 (es) |
| CO (1) | CO6351781A2 (es) |
| CY (1) | CY1113743T1 (es) |
| DK (1) | DK2342182T3 (es) |
| EA (1) | EA021581B1 (es) |
| ES (1) | ES2399177T3 (es) |
| HR (1) | HRP20130038T1 (es) |
| IL (1) | IL210236A (es) |
| MX (1) | MX2011001786A (es) |
| MY (1) | MY164998A (es) |
| NZ (1) | NZ591265A (es) |
| PL (1) | PL2342182T3 (es) |
| PT (1) | PT2342182E (es) |
| RS (1) | RS52674B (es) |
| SI (1) | SI2342182T1 (es) |
| SM (1) | SMT201300020B (es) |
| TW (1) | TWI454461B (es) |
| WO (1) | WO2010028655A1 (es) |
| ZA (1) | ZA201103119B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008131779A1 (en) | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
| KR20110026429A (ko) | 2008-06-23 | 2011-03-15 | 하. 룬드벡 아크티에셀스카브 | Ｎｋ3 길항제로서의 이소퀴놀리논 유도체 |
| AR073891A1 (es) | 2008-10-20 | 2010-12-09 | Lundbeck & Co As H | Derivados de isoquinolinona antagonistas de receptores nk3, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de psicosis, alzheimer y otras enfermedades. |
| TW201143768A (en) | 2009-12-15 | 2011-12-16 | Lundbeck & Co As H | Pyridone derivatives as NK3 antagonists |
| TW201144311A (en) * | 2010-03-12 | 2011-12-16 | Lundbeck & Co As H | Azaisoquionolinone derivatives as NK3 antagonists |
| KR20140090665A (ko) * | 2011-11-09 | 2014-07-17 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 포스포디에스테라제 타입 １０ａ의 억제제로서 유용한 헤테로사이클릭 카복스아미드 |
| MX2020011376A (es) * | 2018-04-27 | 2021-02-09 | Sojournix Inc | Formas polimórficas y amorfas de isoquinolinona y métodos de uso de estas. |
| WO2023152888A1 (ja) * | 2022-02-10 | 2023-08-17 | カルナバイオサイエンス株式会社 | フルオロイソキノリン化合物およびその製造法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9825554D0 (en) * | 1998-11-20 | 1999-01-13 | Smithkline Beecham Spa | Novel Compounds |
| JP2004525183A (ja) * | 2001-04-11 | 2004-08-19 | グラクソスミスクライン・ソシエタ・ペル・アチオニ | Ｎｋ−３およびｎｋ−２受容体アンタゴニストとしてのキノリン−４−カルボキサミド誘導体 |
| GB0509405D0 (en) * | 2005-05-10 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
| WO2008131779A1 (en) * | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
-
2009
- 2009-09-11 SI SI200930492T patent/SI2342182T1/sl unknown
- 2009-09-11 NZ NZ591265A patent/NZ591265A/xx not_active IP Right Cessation
- 2009-09-11 EP EP09776285A patent/EP2342182B1/en active Active
- 2009-09-11 BR BRPI0917245A patent/BRPI0917245B8/pt not_active IP Right Cessation
- 2009-09-11 WO PCT/DK2009/050237 patent/WO2010028655A1/en active Application Filing
- 2009-09-11 ES ES09776285T patent/ES2399177T3/es active Active
- 2009-09-11 CA CA2732612A patent/CA2732612C/en not_active Expired - Fee Related
- 2009-09-11 PL PL09776285T patent/PL2342182T3/pl unknown
- 2009-09-11 RS RS20130036A patent/RS52674B/en unknown
- 2009-09-11 MX MX2011001786A patent/MX2011001786A/es active IP Right Grant
- 2009-09-11 MY MYPI2011001144A patent/MY164998A/en unknown
- 2009-09-11 CN CN200980136727.XA patent/CN102149685B/zh not_active Expired - Fee Related
- 2009-09-11 DK DK09776285.0T patent/DK2342182T3/da active
- 2009-09-11 PT PT97762850T patent/PT2342182E/pt unknown
- 2009-09-11 JP JP2011526372A patent/JP5536776B2/ja not_active Expired - Fee Related
- 2009-09-11 AU AU2009291309A patent/AU2009291309B2/en not_active Ceased
- 2009-09-11 KR KR1020117005880A patent/KR101638641B1/ko active IP Right Grant
- 2009-09-11 EA EA201170447A patent/EA021581B1/ru not_active IP Right Cessation
- 2009-09-14 AR ARP090103522A patent/AR073511A1/es active IP Right Grant
- 2009-09-14 TW TW098130900A patent/TWI454461B/zh not_active IP Right Cessation
-
2010
- 2010-12-23 IL IL210236A patent/IL210236A/en active IP Right Grant
-
2011
- 2011-03-04 CO CO11026657A patent/CO6351781A2/es not_active Application Discontinuation
- 2011-03-14 CL CL2011000533A patent/CL2011000533A1/es unknown
- 2011-04-28 ZA ZA2011/03119A patent/ZA201103119B/en unknown
-
2013
- 2013-01-17 HR HRP20130038AT patent/HRP20130038T1/hr unknown
- 2013-02-06 CY CY20131100105T patent/CY1113743T1/el unknown
- 2013-02-13 SM SM201300020T patent/SMT201300020B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6351781A2 (es) | Derivados de isoquinolinona como antagonistas de nk3 | |
| CL2020001919A1 (es) | Inhibidores de endonucleasa cap-dependientes. | |
| AR060591A1 (es) | Compuestos imidazo | |
| AR072198A1 (es) | Derivados de isoquinolinona como antagonistas de nk3 y composiciones farmaceuticas que los contienen | |
| AR060590A1 (es) | Compuestos imidazo | |
| AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
| PE20091429A1 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne) | |
| PE20080841A1 (es) | Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion | |
| ECSP11010830A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
| PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| AR061603A1 (es) | Derivados de etenilcarboxamidas microbicidas | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| AR054799A1 (es) | Derivados de oxindol | |
| AR079497A1 (es) | Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a | |
| UY32475A (es) | Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen | |
| AR069480A1 (es) | Derivados de 2-amino-pirimidina | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR060813A1 (es) | Moduladores de mglur5 iii | |
| AR059094A1 (es) | Derivados de ciclohexil - sulfonamida | |
| ECSP099351A (es) | Compuestos heterociclicos y su uso como inhibidores de la | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa | |
| AR060652A1 (es) | Moduladores de receptor glutamato metabotropico subtipo 5 (mglur5 ii) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |